• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purinones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Purinones

6H-Purin-6-one,1,9-dihydro-2-(methylthio)-: A Promising Compound in Modern Biomedical Research

6H-Purin-6-one,1,9-dihydro-2-(methylthio)- (CAS No. 5446-89-9) has emerged as a critical molecule in the field of biomedical science, particularly in the exploration of its structural properties and biological activities. This compound belongs to the purine derivative family, which is widely studied for its role in nucleotide synthesis and metabolic pathways. Recent advancements in molecular biology and pharmacology have highlighted the potential of 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- as a candidate for therapeutic applications, including its anti-inflammatory, antiviral, and antitumor properties.

Research published in Journal of Medicinal Chemistry (2023) has demonstrated that the 1,9-dihydro-2-(methylthio) functional group in this compound plays a pivotal role in modulating its interaction with specific enzymes. The methylthio substituent, for instance, enhances the compound's ability to inhibit adenosine deaminase, a key enzyme in purine metabolism. This finding aligns with the broader trend in drug discovery where structural modifications are leveraged to optimize pharmacological profiles. The 6H-Purin-6-one scaffold, a core component of many nucleoside analogs, further contributes to the compound's stability and bioavailability, making it a favorable candidate for further development.

Recent studies have also explored the 6H-Pur-6-one moiety's potential in targeting RNA viruses. A 2024 paper in Antiviral Research reported that 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- exhibits selective antiviral activity against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The compound's ability to interfere with viral RNA replication mechanisms is attributed to its unique structural features, which allow it to bind to specific viral enzymes with high affinity. This discovery underscores the importance of 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- in combating emerging infectious diseases.

Another area of interest is the compound's role in modulating immune responses. A 2023 study in Immunology Letters highlighted that 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- can suppress excessive inflammation by inhibiting the NF-κB signaling pathway. This property is particularly relevant in autoimmune disorders and chronic inflammatory conditions, where uncontrolled inflammation leads to tissue damage. The methylthio group appears to be crucial in this mechanism, as it enhances the compound's ability to cross the blood-brain barrier, allowing it to exert its effects in central nervous system disorders.

From a synthetic perspective, the 6H-Purin-6-one core is often synthesized via a nucleophilic attack on a purine ring, a reaction that can be fine-tuned to introduce functional groups like the methylthio substituent. This synthetic flexibility has enabled researchers to explore a wide range of derivatives, each tailored for specific therapeutic applications. For example, a 2024 patent application described a series of 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- derivatives with improved solubility and reduced toxicity, addressing key challenges in drug development.

The compound's potential in oncology is another area of active research. A 2023 preclinical study published in Cancer Research showed that 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- can induce apoptosis in cancer cells by targeting the p53 tumor suppressor pathway. This effect is particularly notable in leukemia and lymphoma models, where the compound demonstrated significant efficacy without causing substantial damage to healthy cells. These findings suggest that 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- could be a valuable addition to the arsenal of antitumor agents.

Despite its promising properties, the compound's therapeutic potential is still under investigation. Challenges such as its metabolic stability and potential side effects require further study. However, the growing body of evidence supporting its efficacy in multiple disease models has positioned 6H-Purin-6-one,1,9-dihydro-2-(methylthio)- as a key player in the next generation of biomedical therapies. As research continues, the compound's role in addressing complex health challenges is likely to expand, driven by its unique structural and functional attributes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)